This Stock Just Got Cheaper on Better Numbers
A debt-free American manufacturer now trades at roughly 7x annualized Q2 EBITDA, with $7.35 per share in net cash and a tender floor 18.5%…
Sector
Everything our editor has picked under this sector, best first.
68 stories
A debt-free American manufacturer now trades at roughly 7x annualized Q2 EBITDA, with $7.35 per share in net cash and a tender floor 18.5%…
A name for @dirtcheapstocks and @dirtcheapbanks... $ETD. $600 mkt cap, $133MM in cash, no debt. Generated $40MM+ in cash flow last year. They also have extensive real estate holdings (unencumbered) which could be worth $175-$275MM. They pay a regular dividend of $0.39/quarter which is about a 7.0% yield. For the past 6-years they've used any excess FCF to pay special dividends to shareholders. The stock trades at 1.5x book (which is clearly understated). Seems like someone should buy this biz.
@dirtcheapstocks $BRK traded between $40 and $49 in Q4 1974. Book was $90 per share. https://t.co/rOzWLipg1U
Biorem reported 66% revenue growth and over 260% profit growth after trading at 11.3 times earnings and 5.9 times EV/EBITDA.
Excellent quarter for Skyline Bankshares $SLBK. GAAP EPS $0.89. Cash EPS of $0.91. Trades at 7x earnings. https://t.co/7d5KOoG3Og
Anybody like $DOMO here? Trading at $3.67 when they will have circa $4.84 in net cash after the sale closes + $900m in NOLs (at a 21% tax rate, that's worth $4.50 to the equity) https://t.co/UwaAd0UkLL
$SSTK -- this stock was often trading below 8x p/e throughout the last 3 years and even lower on a net cash basis. At the start of this year it was trading around 4.5x p/e. It's down 70% YTD https://t.co/aRCDW2mTMu
$ROL ugly quarter, hate when the call is the following day (same with $MEDP) but as much as Ive beat it up on valuation over the past few years it finally starts to enter the interesting zone under $35. demographic trends to TX and the SE favor increased pest control over time, recurring service, start pushing 15-18x in the low 30s Research considerations - would be curious to see how increased PE movement into the space in different markets continues to impact density and lead generation and pricing as well as m&a opportunities before pulling the trigger here. Not a luxury but an essential service in my neck of the woods.
$STLE Steele Bancorp posted another strong quarter. Reported earnings are $0.20 below cash earnings due to intangible amortization. At a $7 annual cash EPS run rate. Trading at just over 6x cash earnings. 3.5% dividend yield. https://t.co/uY7m0VofSe
Alpha where you least expect it... Over the past 3-months the FURNITURE space has delivered monster upside relative to the indices. Many of these legacy companies have pristine balance sheets, generate cash, and continue to modestly grow their order books despite the ongoing weakness in housing. These stocks in some cases were trading at close to zero EV ($BSET, $ETD) when including their real estate holdings. They remain cheap and have tons of earnings leverage to a housing upturn. 3-month returns: $BSET 47.7% $BOBS 30.8% $HOFT 17.5% $WSM 17.2% $LZB 14.7% $HVT 13.3% $SPX 6.4%
Forget AI. Big Pharma is telling us where the next mega theme is. As some have postulated, health care is undergoing extraordinary change. From GLP1s to Peptides to value based Oncology care ($TOI) and of course - the emerging frontier of Psychedelics. $STIM owns the clinical distribution infrastructure for this new space. And the current stock price embeds zero (or negative) equity value for their asset. h/t: @QTRResearch
If a company is OTC listed and consistently reducing its share count, it seems like a high percentage of the time, it works out well... $MCEM $WEBC $APTL $FMBL $BWEL(?)
A debt-free machine tool company with $50 million in cash trades at 0.74 times book value and below net current asset value.
$FIS I appreciate the ai narrative and stable coins narrative for broad payment sector names...but $FIS at current prices seems like a good Depp value opportunity. In general the rubber band seems very far stretched between the momentum names in semi capX and the ai "losers" and mega cap tech. Whether its sell the news on $MU earnings, end of quarter rebalancing etc, seems we are on the cusp of a rotation. (even if its only short lasting, should be quite volatile as we say several weeks ago). [going long Amzn, select software, fis, select med tech to play that versus short the SOXX, some derivative names like $CAT]
$BSX ?? flat over the past 5 years. Can point to slowing growth from very elevated levels as farapulse and watchman have larger bases, some competition entering these spaces, glp1 on the margin to case loads over time, new inhibitors that could be coming from Lilly, novo, but at current $ sure seems like a lot is baked in at current prices. Innovative cardio franchise that has: Revenue has effectively doubled - predominately from farapulse and watchman (not m&a) Operating income 1.8B to 4.1B EBIT - $1.4B to 4.1B 3.5x on EPS (.69 to $2.40/share current) gross, operating, net, ebit, ebitda margins all expanded over that timeframe FCF more than 2x, opcf 2.5x The difference is you get to buy it at the same share price today, shares outstanding are virtually flat. Perhaps the defensive nature of medtech is sold in the aggressive risk on market we are in but growth still solid here with dividend and margin of safety versus other areas certainly seems worth a look, as is the rest of medtech as a place to hunt for value to wait until the market rotates back
A software powerhouse posts a record quarter while trading at a 52-week low, raising a valuation disconnect between its business model and…
$UTGN looked promising as an illiquid deep value sit with buybacks at way below IV, but this relatively recent option grant struck below NAV seems like a thesis killer. Anybody know the name well?
Wild to me that when $MAPS was trading 2x higher, it was a seemingly beloved consensus long on here, and now due to STRATEGIC delisting it's traded off massively, sits at net cash, all while generating $40 mm of EBITDA.
Solid quarter by Monument Mining $MMY.V $MMTMF earned $22.65M or $0.07 per share. Has almost $101M or $0.30 per net cash. Trading at ~ 2x earnings net of cash. https://t.co/c56aqhOJuY
GPK · long Graphic Packaging (GPK) is pitched as a long with $22 fair value, implying roughly 100% upside, based on its low-cost paper-based packaging…
PayPal’s valuation implies free cash flow will shrink 9.3% annually over the next decade, framing a long thesis against its recent revenue…
$TIPT filed an 8-K this morning where they said they expected the Fortegra deal to close by Friday 5/29. Pro forma TBV is ~$24/share, stock last 17.17.
I don't know if I fully agree with that. $CBBI trades at 0.4x for two reasons: 1) OTC listing and 2) no buyback. If there was a company sponsored buyback, it would probably trade at 0.6-0.7x and therefore the buybacks would be less accretive. Also if you look at my numbers you'll see that the projected share price in the non-buyback scenario is $16.16 in five years plus $2.50 in dividends vs. $19.10 in the buyback scenario. Pretty close. If you're a short-term holder, you want the buyback to re-rate this to 0.6-0.7x. If you want to long-term compound, it's not clear the buyback is that much better to me.
$CBBI followers- the tables below show two scenarios assuming a sale in 5 years at 100% of TBV: 1) Investor reinvests the .50/yr dividend into more shares 2) CBBI suspends dividend and instead does a share repurchase The analysis shows that the results are roughly the same (BEFORE TAXES). The point here is to show that if you reinvest your dividend you can somewhat replicate the economics of a buyback. One assumption that is likely optimistic in the company buyback scenario is that they'd continue to be able to buy back at 0.4x TBV. If you tinker with that, the buyback is less valuable. cc: @mwphnh